CTD Dossier Templates for the US and EU Regulatory Authorities
Accelerate Your Path to Market with Zenovel’s expert regulatory solutions from IND to MAA
Accelerate Your Path to Market with Zenovel’s expert regulatory solutions from IND to MAA
Zenovel provides Customized Common Technical Document (CTD) dossier templates for regulatory submissions to US and EU agencies, simplifying the preparation and submission of pharmaceuticals and biologics documentation, as they meet unique standards set by the EMA and the US FDA.
We offers customized CTD dossier templates for various regulatory applications, including INDs, IMPDs, MAAs, BLAs, NDAs, and ANDAs for pharmaceutical and biological goods, making them easier to understand and utilize.
Our IND templates simplify the authoring and submission of Phase I, II, and III clinical trial applications to the US FDA. These templates provide detailed information on regulatory requirements for biological and pharmaceutical goods, allowing applicants to comply with FDA expectations. The metadata also provides in-depth information on potential clinical-hold problems related to Clinical Management Control (CMC) requirements and advice on handling CMC-related clinical-hold problems.
We have developed CTD templates for US and EU biologics marketing authorization dossier submissions. These templates are encrypted with specific metadata for each agency and application, providing guidance on regulatory requirements and potential issues like application-hold and refuse-to-file. The metadata also outlines standard specifications for biological products and production processes. The applicant can adhere to unique metadata for each application type and agency, and the same CTD data package can be updated or modified for the next country-submission.
We has personalised templates simplify the creation and submission of an IMPD for clinical programmes to EU HAs and member states. These templates must satisfy pharmaceutical and biological product regulations, allowing applicants to adhere to metadata based on product type to meet HA needs and expectations.
Pharmaceutical product innovators can file for innovations in generic pharmaceuticals under the FDC Act by altering formulation, components, administration method, dosage schedule, and API using customised NDA 505(b) 2 templates. These templates provide regulatory references for most RTR concerns for all types of pharmaceutical products, including tablets, capsules, solutions, suspensions, injectable, and topical.
Insufficient understanding of GDUFA II, RTR prerequisites, and ANDA readiness can lead to ANDA rejections, costing company’s time and money. To avoid this, company should submit an ANDA using the correct data presentation strategy, including in-depth details and regulatory references for various generic medicine dosage forms.
MAA CTD templates have been prepared for EU MAAs relating to pharmaceutical items, containing encrypted metadata outlining regulatory requirements for generic pharmaceutical goods in various formulation forms such as tablets, capsules, solutions, suspensions, and injectables, to be submitted via relevant processes.
Ensure your submission meets highest standards by our deep understanding of the regulatory process- US and EU authorities.
Our pre-formatted templates and checklists are easy to edit, allowing you to customize documents.
For product registration, each template is encrypted with specific metadata prepared by regulatory experts.
Pharmacovigilance (PV), the scientific process of detection, assessment, understanding, and prevention of adverse drug reactions, is going to be revolutionized in 2025. PV is evolving from a more reactive to a proactive discipline, aided by new and evolving technologies, including quantum-enhanced AI, global safety monitoring in real time, and other
In the world of globalized pharmaceutical industry, clinical trials and regulatory affairs are becoming ever more international in terms of languages and cultures. India is well on the way to becoming a global pharmaceutical hub in 2025, now is the time to ensure that we get accurate translation and localization
The Indian pharmaceutical industry, a global leader and the third-largest medicine producer by volume, is renowned for providing cost-effective, high-quality drugs worldwide. In 2025, new regulatory frameworks and stringent compliance requirements are being implemented, compelling Indian pharma companies to adapt. These reforms aim to enhance credibility, safety, and global competitiveness,
Steps to Optimize Your Regulatory Affairs Process Regulatory affairs professionals in medical technology are crucial in ensuring compliance and market entry. Such professionals face challenges in navigating registration processes, fostering collaboration, and utilizing data-driven insights. Innovative regulatory solutions can enhance efficiency and improve outcomes. This blog presents five transformative strategies
In the fast-paced and highly regulated world of pharmaceuticals and nutraceuticals, following Good Manufacturing Practices (GMP) is vital for assuring safety, quality, and regulatory compliance. Dealing with the intricacies of GMP standards can be overwhelming, requiring extensive technical knowledge and strategic assistance. A reliable GMP consultants can provide valuable assistance.
Drug discovery to market approval is a lengthy and arduous endeavor, lasting a year or more while taking an enormous amount of resources and finances. Among the various processes in going from discovery to market, Chemistry, Manufacturing, and Controls (CMC) is essential in establishing that drugs are safe and effective
